We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CFDA Plans Reforms in Approvals and Clinical Trials Processes
CFDA Plans Reforms in Approvals and Clinical Trials Processes
The China Food and Drug Administration is taking public comments on four proposed reforms, covering the review of new drug applications, the deregulation of clinical trials, postmarket surveillance and intellectual property rights.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor